Sales growth driven by continued strong performance from Entresto (+31% cc), Cosentyx (+25% cc), Kesimpta (+49% cc), Kisqali (+49% cc), Pluvicto (+42% cc) and Leqvio (+114% cc) Core operating income ...
Background: Spinal and bulbar muscular atrophy (SBMA) or Kennedy disease [OMIM ... consent form and allowed anonymised publication of their clinical information and photos. The study included all ...
Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback